Earnings call transcript: Kamada Ltd. misses Q4 2025 forecasts, stock dips

Kamada missed Q4 estimates with EPS $0.06 vs $0.10 consensus (40% miss) and revenue $44.68M vs $45.42M, prompting a ~3.01% pre-market share drop. Full-year 2025 revenue rose 12% to $180.5M and net income climbed 40% to $20.2M ($0.35/sh), adjusted EBITDA $42M (+23%), and the board declared a $0.25/share dividend. Management reaffirmed strong 2026 guidance (revenues $200M–$205M; adj. EBITDA $50M–$53M), provided quarterly EPS and revenue forecasts (e.g., Q2 EPS $0.11, Q2 revenue $49.4M), and highlighted growth drivers (plasma centers, biosimilars, distribution, M&A). Market metrics: market cap ~$467.7M, P/E ~23.18, PEG ~0.58, and Street consensus remains Strong Buy with $11–$15 targets (upside to ~59%).

Analysis

The company’s structural optionality is underpriced: verticalizing plasma sourcing creates a nonlinear cost advantage versus third‑party suppliers once internal volumes cross a modest inflection point. If management converts even a minority of specialty plasma needs to captive supply, gross margin expansion and free cash flow upside will accelerate materially because each incremental liter displaces high-cost purchases and shortens working capital cycles.

Distribution and biosimilar expansion create asymmetric upside with concentrated downside risk. Winning tenders or expanding into adjacent geographies can rapidly scale low‑margin distribution into a higher‑margin, recurring revenue stream, but the same channels amplify competitive pricing pressure; players with deeper local logistics or tender-scale will be hardest hit. Strategic partnerships that convert royalties into predictable annuities will de‑risk revenue more than incremental product launches alone.

Short-term volatility is the primary investor hazard; operational beats/misses will swing sentiment given modest market liquidity. Key binary catalysts that will reprice the story are cadence and quality of incremental captive plasma volumes, clinical/regulatory signals that change product utilization dynamics, and any M&A that either consumes cash or accelerates scale. Time horizon for meaningful de‑risking is multi‑quarter to multi‑year, so trade framing should reflect optionality rather than near‑term earnings smoothing.

Key Decisions for Investors

• Initiate a selective long: accumulate KMDA-sized position equal to 2–4% of risk capital on 5–10% post‑earnings weakness, horizon 12–18 months. Rationale: asymmetric upside from captive plasma scaling and distribution leverage; set hard stop at 25% to cap drawdown if margin trends deteriorate.
• Buy call spread (KMDA) to cap premium but retain convexity: buy 9–12 month call 30% OTM and sell a far OTM call ~80% above entry to fund premium. Risk limited to debit; target 3x–5x payoff if operational execution and tender wins accelerate revenues.
• Pair trade to isolate company‑specific execution risk: long KMDA / short an incumbent plasma/IG supplier (e.g., GRFS) in equal dollar notional for 6–12 months. Thesis: KMDA’s path to vertical integration should outpace legacy peers; unwind if sector breadth turns strongly positive.
• Event‑driven alerting: set automated triggers for (a) regulatory approvals for any collection facilities, (b) >quarterly inflection in captive plasma contribution to COGS, and (c) major tender/partnership announcements. Re‑size positions opportunistically on confirmed readouts.